PolyPEPI™ Immunotherapy Cancer Vaccine Family
Using our cancer vaccine platform we completed the preclinical development of PolyPEPI™ immunotherapy vaccines for colorectal cancer, breast cancer, lung cancer, ovarian cancer, glioma, melanoma, and leukemia. We expect to advance the colorectal cancer vaccine to the first-in-man trial in 2017.
Our in silico clinical trials predict our vaccines to be effective in significant proportion of cancer patients, with reliable predictions of individual responses to treatment and minimal safety concern. We plan to conduct clinical trials that will enroll only those cancer patients identified by our companion diagnostic test to be likely responders.
Each PolyPEPI™ vaccine has four essential immunological design features:
- Safety – attacking only cancer cells and not healthy cells
- Potency – killing multiple varieties of cancer cells
- Efficacy – producing an immune response in a significant proportion of cancer patients
- Personalization – identifying likely responders before treatment